RLYB
What one share of Rallybio holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases.
Rallybio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.11 |
|---|---|
| Profit | $7.99 |
| Cash and investments | $17.50 |
| Book value | $17.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$12.17 | $0.06 | −$10.20 | — | $46.48 |
| 2021 | — | −$14.74 | $0.10 | −$14.38 | — | $43.72 |
| 2022 | — | −$16.76 | $0.01 | −$14.41 | — | $35.80 |
| 2023 | — | −$14.75 | $0.00 | −$11.92 | — | $22.46 |
| 2024 | $0.12 | −$10.61 | $0.00 | −$9.05 | — | $11.88 |
| 2025 | $0.15 | −$1.59 | — | −$5.30 | — | $10.97 |